Rx Safety Triggers Tighten As Senate Continues Work On FDA Revitalization Act
Executive Summary
Provisions that specify which information will trigger the requirement for a drug to have a Risk Evaluation and Mitigation Strategy have been added to the FDA Revitalization Act as Senate floor debate on the bill continues
You may also be interested in...
FDA Reform Bill Leaves Senate With Reduced Safety Powers But Stiffer Fines
Legislation to reauthorize FDA's user fee program and expand the agency's oversight powers on drug safety has cleared the Senate with much stronger fines than originally envisioned by the sponsors, thanks to an amendment by Sen. Charles Grassley, R-Iowa
FDA Reform Bill Leaves Senate With Reduced Safety Powers But Stiffer Fines
Legislation to reauthorize FDA's user fee program and expand the agency's oversight powers on drug safety has cleared the Senate with much stronger fines than originally envisioned by the sponsors, thanks to an amendment by Sen. Charles Grassley, R-Iowa
Sen. Coburn Plays It Safe; FDA Will Review Medical Marijuana But Not RU-486
A path to federal legalization of state-sanctioned medical marijuana was approved by the Senate Health, Education, Labor and Pensions Committee as part of the markup of a bill renewing FDA's user fee program